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Time for a Policy Change for
Coronary Artery Calcium Testing
in Asymptomatic People?*
Philip Greenland, MD,† Tamar S. Polonsky, MD‡
Chicago, Illinois
Recent clinical practice guidelines for coronary artery cal-
cium (CAC) testing in asymptomatic people vary in their
advice about routine testing from moderately enthusiastic
support to frank opposition. The 2010 Clinical Practice
Guideline Panel of the American College of Cardiology and
the American Heart Association (ACC/AHA) published
an extensive published data review and assessment of the
utility of a large number of tests and procedures for risk
assessment of the asymptomatic adult (1). Recommenda-
tions for CAC scoring ranged from Class IIa (reasonable to
perform the procedure) to Class III (should not be done).
See page 1690
The ACC/AHA recommendations for CAC testing, by
different patient categories, are shown in Table 1. Level of
evidence for all of the ACC/AHA CAC recommendations
was regarded as B, primarily because there are no random-
ized trials that have tested the role of CAC scoring in
asymptomatic patients for evidence of improved health
outcomes (1). At the opposite end of the spectrum, a 2009
report from the U.S. Preventive Services Task Force con-
cluded that “current evidence does not support the routine
use” of CAC testing for risk stratification of intermediate-
risk persons (2). The U.S. Preventive Services Task Force
generally looks for randomized trial evidence and, in its
absence, advises against testing as it did for CAC screening.
The Institute of Medicine reflected uncertainty in this area,
despite enthusiastic support from certain groups in the
clinical community (3), and listed CAC testing for routine
risk assessment as 1 of its Top 100 areas of priority for
comparative effectiveness research (4). Furthermore, the
Institute of Medicine placed an emphasis on assessing the
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to the contents of this paper to disclose.effect of CAC testing on actual CHD outcomes. Common
to all of these reports is the awareness that there is no
randomized trial evidence to show true clinical benefit,
owing to CAC testing. So the risks—which include addi-
tional healthcare costs, inconvenience, radiation exposure,
and the discovery of incidental abnormalities that might
require invasive and expensive work-up— cannot be
weighed against proven benefits such as reduced coronary
morbidity and mortality.
New evidence has emerged in the last year since the previous
recommendations and guidelines were generated, and it has
been stated by some that the new evidence now supports a
mandate for routine CAC testing (5). Rather than a clinical
rial, the new evidence comes from 3 large and carefully done
bservational studies (MESA [Multi-Ethnic Study of Athero-
clerosis]; HNR [Heinz Nixdorf Recall Study]; and the Rot-
erdam Study) that evaluated the risk reclassification capability
f CAC testing after routine risk factor assessment with a
linical tool such as the Framingham Risk Score (6–8). As we
howed from the MESA study in 2010, during a median of 5.8
ears of follow-up among a cohort of 5,878 asymptomatic
ndividuals, addition of CAC score to the Framingham risk
actors resulted in significant improvements in risk prediction
f coronary events (net reclassification improvement  0.25).
pproximately 10% of the cohort was newly classified into
ither the highest- or lowest-risk categories, possibly indicating
he appropriateness of greater—or lesser—intensity of preven-
ive treatments. An additional 23% of those who experienced
vents were reclassified as high risk, and an additional 13%
ithout events were reclassified as low risk with CAC in
ddition to traditional risk factors. We concluded that addition
f CAC to a prediction model based on traditional risk factors
ignificantly improved the classification of risk and placed more
ndividuals in the most extreme risk categories. We also
cknowledged that additional clinical trial evidence was needed
efore concluding that CAC testing should be routinely
erformed in the clinical setting (6).
The report in this issue of the Journal by van Kempen
t al. (9) addresses the role of CAC testing in asymptomatic
ndividuals with cost-effectiveness analysis (CEA) and com-
arative effectiveness analysis. Its primary conclusion is that
creening for CAC with CT in individuals at intermediate
isk of CHD is probably cost-effective in men but is unlikely
o be cost-effective in women. The CEA uses recent
vidence on risk reclassification from the Rotterdam Study
7) to design competing risk assessment strategies, so this
eport is the most up-to-date CEA on this topic. How
hould this new report influence the thinking about routine
AC testing? And is this sufficient to avert a clinical trial to
ore fully address the topic?
The discussion by van Kempen et al. (9) recognizes a
umber of concerns that must be considered. First, the
uthors cite limitations of their work, including the focus
nly on intermediate-risk patients, so the recommendations
hould be limited only to this category of patients. This is
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category most frequently discussed as likely to benefit from
risk reclassification. More importantly, the authors note
that, as with all models of screening and diagnostic tests, the
differences between the various strategies in terms of
quality-adjusted life years were small. There was considerable
uncertainty demonstrated in the sensitivity analyses, such that
the optimal strategy could be routine CAC testing but might
also be moderate dose “statin therapy” for everyone not already
taking statins (nearly a “treat all” option). Additionally, al-
though neither “current practice” nor “current guidelines”
emerged as the dominant strategy in these models, if Adult
Treatment Panel guidelines are updated to expand the indica-
tions for statins, it is possible that they will be more commonly
used in routine practice. As a result, CAC testing could
become less valuable in selecting patients for statin treatment
and improving clinical outcomes. All of these scenarios lead to
the conclusion that additional information beyond that avail-
able from the CEA by van Kempen et al. (9) might be needed,
before a convincing and definitive change in clinical practice
guidelines would be justified.
Several recent articles have advocated alternative ap-
proaches in preventive cardiology rather than more “person-
alized” assessment of cardiovascular risk with biomarkers
such as CAC (10–12). Hingorani and Psaty (12), in an
editorial published in 2009, posed the question: “Is it time
to get more or less personal in primary prevention of
cardiovascular disease?” Their main point—which is re-
flected in all risk prediction models, including those that
incorporate CAC (6–8)—is that the models are neither
highly sensitive nor highly specific. Although the treatment
thresholds of the models can be adjusted to achieve higher
sensitivity, when this is done, specificity is very poor and
treatment would need to be widespread (13). Commonly
used risk prediction models such as the Framingham Risk
Score, when using a threshold for treatment above 20% in
10 years, miss large numbers of patients destined to develop
an event. Slightly lower risk thresholds also miss large
numbers of cases. For example, in the MESA study (5),
with 209 CHD events occurring over 5 years, 57 (27%)
occurred in patients predicted to be in the lowest-risk group
(predicted risk 3% in 5 years). Even the addition of CAC
o the Framingham risk factors still classified 51 of the 209
eople (24%) who developed near-term events as “lowest
Recommendations for CAC Scoring From the American College of CTable 1 Recommendations for CAC Scoring From the American
Class IIa
1. Measurement of CAC is reasonable for cardiovascular risk assessment in asym
Class IIb
1. Measurement of CAC might be reasonable for cardiovascular risk assessment
Class III: No Benefit
1. Persons at low risk (6% 10-yr risk) should not undergo CAC measurement for
Data from Greenland et al. (1).
CAC  coronary artery calcium.isk.” The Reynolds Risk Score has similar problems inidentifying the highest-risk people (14,15). In the Women’s
Health Study, 44% of the patients who developed cardio-
vascular events were classified in the lowest-risk group on
the basis of traditional risk factors alone. Forty-two percent
of the participants with events still remained in the lowest-
risk category, after adding high-sensitivity C-reactive pro-
tein and family history to the model. In the Physicians
Health Study II, more than 500 CHD events occurred
among men classified as intermediate risk on the basis of
traditional risk factors. Only 13% of the intermediate-risk
participants who experienced events were reclassified to
high risk with the Reynolds Risk Score for Men.
Recognizing problems with so-called “personalized risk”
approaches led Hingorani and Psaty (12) to consider treat-
ment strategies that avoid individual testing and simply treat
with statins everyone above a certain age, a method recom-
mended earlier by Law and Wald (13). This “treat all”
approach emerged as the dominant strategy in some of the
sensitivity analyses by van Kempen et al. (9), yet with
different assumptions in place CAC testing was the “win-
ning” approach.
With the residual uncertainty in this important area of
preventive medicine, we believe that the only way to
determine the “best” strategy is to conduct a clinical trial
with CAC testing to select patients for more or less
intensive treatments. Others have also advocated for such a
trial (16,17). Judging from the very similar results for the
strategies compared in the van Kempen et al. (9) cost-
effectiveness analysis, it is obvious that such a trial would
need to enroll a large number of patients who were followed
for at least 4 to 5 years. The study would be challenging
logistically as well as costly. However, in the absence of such
a trial, the options seem to be so close to one another on
careful analysis that reasonable errors in the assumptions can
lead to very different conclusions. We conclude that there is
not enough evidence, even with the newer data on risk
reclassification, to justify a change in current clinical practice
recommendations. A screening trial with CAC measure-
ment is long overdue.
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